The clinical trial CheckMate-648 has proved that ipilimumab (anti-CTLA-4) combined with nivolumab (anti-PD-1) in first-line treatment could improve overall survival (OS) with durable objective responses and acceptable safety compared to chemotherapy alone for ESCC patients (25). Here, CTLA4 is linked to esophageal squamous cell carcinoma.